Global data show real-world effectiveness of romosozumab for patients at high fracture risk
UCB, a global biopharmaceutical company, today announced findings from a collection of real-world evidence studies to reaffirm the effectiveness and clinical impact of romosozumab, the only dual-acting osteoporosis treatment that…